Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA by Rakhit, Callum P. et al.
RESEARCH ARTICLE
Early detection of pre-malignant lesions in a KRASG12D-driven
mouse lung cancer model by monitoring circulating free DNA
Callum P. Rakhit1,‡, Ricky M. Trigg2,‡,*, John Le Quesne1,2, Michael Kelly3, Jacqueline A. Shaw2,§,
Catrin Pritchard2,§ and L. Miguel Martins1,§
ABSTRACT
Lung cancer is the leading cause of cancer-related death. Two-thirds of
cases are diagnosed at an advanced stage that is refractory to curative
treatment. Therefore, strategies for theearlydetection of lung cancerare
urgently sought. Total circulating free DNA (cfDNA) and tumour-derived
circulating tumour DNA (ctDNA) are emerging as important biomarkers
within a ‘liquid biopsy’ for monitoring human disease progression and
response to therapy. Owing to the late clinical diagnosis of lung
adenocarcinoma, the potential for cfDNA and ctDNA as early detection
biomarkers remainsunexplored.Here, usingaCre-regulatedgenetically
engineeredmousemodel of lungadenocarcinomadevelopment, driven
byKrasG12D (theKrasLSL-G12Dmouse), we serially tracked the release of
cfDNA/ctDNA and compared this with tumour burden as determined by
micro-computed tomography (CT). To monitor ctDNA, a droplet digital
PCR assay was developed to permit discrimination of the KrasLox-G12D
allele from theKrasLSL-G12D andKrasWT alleles.We show that micro-CT
correlates with endpoint histology and is able to detect pre-malignant
tumourswithacombinedvolume larger than7 mm3.Changes incfDNA/
ctDNA levels correlate with micro-CT measurements in longitudinal
sampling and are able to monitor the emergence of lesions before the
adenoma-adenocarcinoma transition. Potentially, this work has
implications for the early detection of human lung adenocarcinoma
using ctDNA/cfDNA profiling.
A video abstract for this article is available at https://youtu.be/
Ku8xJJyGs3U.
This article has an associated First Person interview with the joint first
authors of the paper.
KEY WORDS: KRASG12D, Mouse model, Circulating free DNA,
cfDNA, Early detection, Lung adenocarcinoma
INTRODUCTION
Circulating free DNA (cfDNA) was first identified in the human
bloodstream during the first half of the 20th century (Mandel and
Metais, 1948), although only in the late 1980s was cfDNA isolated
from the plasma of cancer patients, shown to be partially derived
from tumours (Stroun et al., 1987), representing the so-called
circulating tumour DNA (ctDNA) fraction. ctDNA is a reliable
biomarker for identifying oncogenic changes within the body
(Schwarzenbach et al., 2011) and has implications for both the early
detection and monitoring of cancer. Changes in the molecular
profile of ctDNA can be used to detect early-stage cancer lesions
(Cheng et al., 2017), classify the molecular profiles of existing
tumours (Burrell et al., 2013), identify the emergence of resistance
(Diaz et al., 2012) and track the evolution of cancer genomes in
response to targeted drug therapies (Abbosh et al., 2017). In this
regard, ctDNA analysis is transforming the monitoring of cancer
after diagnosis and has been established as a prognostic factor for
lung cancer patients (Cabral et al., 2010; Goebel et al., 2005).
Monitoring a patient’s ctDNA profile is less invasive than tissue
biopsy, with the reduced stress and cost allowing for more frequent
sampling. Repeat sampling allows for more targeted, personalised
therapy in the face of tumour evolution. ctDNA may also have the
potential to enable the discovery of newly emergent cancers,
undetectable by imaging or other diagnostic procedures (Abbosh
et al., 2017; Chaudhuri et al., 2017; Garcia-Murillas et al., 2015).
Accordingly, ctDNA profiling approaches are being developed to
improve the monitoring and characterisation of residual disease in
lung cancer, which could help improve outcomes in the adjuvant
disease setting (Abbosh et al., 2017). However, the genetic profiling
of ctDNA in individuals with early disease lesions has been limited,
due to inherent challenges in building a cohort of study patients with
identifiable pre-malignant lesions.
Gain-of-function mutations in KRAS are present in ∼25% of
human lung adenocarcinomas and are truncal events, acquired early
in disease development (Abbosh et al., 2017; Rakhit et al., 2017).
Oncogenic mutants of KRAS, such as the prevalent KRASG12D
mutation, have transforming activity and are thought to be founder
mutations as they can initiate and drive tumour progression in mouse
models (Guerra et al., 2003; Jackson et al., 2001; Sutherland et al.,
2014). The autochthonous KrasLSL-G12D conditional mouse knock-in
model, which allows for endogenous expression of KrasG12D
following Cre induction, has been used extensively to study the
mechanisms underpinning early disease initiation and maintenance
(Jackson et al., 2005; Jackson et al., 2001; Sheridan and Downward,
2015; Sutherland et al., 2014). Evidence shows that the model
recapitulates early-stage lung adenocarcinoma development, through
the formation of atypical adenomatous hyperplasia (AAH), epithelial
hyperplasia of the bronchioles and papillary adenomas (Jackson
et al., 2001; Nikitin et al., 2004). Early-stage lung adenocarcinomas
are occasionally seen at late stages, following prolonged KrasG12DReceived 17 August 2018; Accepted 21 December 2018
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expression, and can be accelerated by a combined p53 (also known as
Trp53) mutation (Jackson et al., 2005).
Here, we use theKrasLSL-G12Dmousemodel to explore the utility of
both total cfDNA levels and ctDNA as an early-stage biomarker. We
show that cfDNA/ctDNA is detectable in mice bearing pre-malignant
lung lesions, prior to the adenocarcinoma transition, and we correlate
the liquid biopsy data with the emergence of pre-malignant lung
lesions as detected by longitudinalmicro-computed tomography (CT).
RESULTS
Comparing tumour size and number in Kras+/Lox-G12D mice
using micro-CT and histology
To induce expression of KRasG12D in the mouse lung, adenoviral-
Cre vectors are delivered to Kras+/LSL-G12D mice using intranasal
delivery (Fig. 1A), and the most commonly used viruses used for
this purpose are either Ad5-CMV-Cre or Ad5-mSPC-Cre (Jackson
et al., 2001; Sutherland et al., 2014). With Ad5-CMV-Cre, the Cre
recombinase is expressed from the ubiquitous cytomegalovirus
(CMV) promoter and generates a range of lung pathologies
including AAH/adenoma and bronchial hyperplasia (BH)
(Jackson et al., 2001). Ad5-CMV-Cre is also known to induce
recombination of the KrasLSL-G12D allele in lung resident myeloid
cells as well as features of the Langerhans cell histiocytosis
phenotype (Kamata et al., 2017). In the case of Ad5-mSPC-Cre, the
Cre recombinase is expressed from the mouse surfactant protein C
(SPC; also known as Sftpc) promoter, allowing more restricted
expression of KrasG12D to alveolar type II cells and inducing the
development of AAH/adenoma (Sutherland et al., 2014). With both
models, overt adenocarcinomas are detectable at a low frequency
over prolonged periods (Jackson et al., 2001; Sutherland et al.,
2014). A previous study has shown a good correlation between
micro-CT and histology using the Kras+/LSL-G12D model infected
with Ad5-CMV-Cre. Therefore, we focused on extending this
analysis to Kras+/LSL-G12D mice infected with Ad5-mSPC-Cre.
We examined the dynamic range for tumour detection in
Kras+/LSL-G12D mice at 40 weeks postinfection (p.i.) with Ad5-
mSPC-Cre by comparing the tumour burden at endpoint using
histology andmicro-CT (Fig. 1A). The lesions detected at this endpoint
were heterogeneous in size (Fig. 1A, iii). We found that the number of
tumours observed by histology was significantly higher (P<0.01) than
Fig. 1. Comparison of micro-CT
imaging and histological analysis
of tumours for measuring tumour
burden. (A) Schematic of the
KrasLSL-G12D allele. Expression of
Cre recombinase allows for removal
of the LoxP-STOP-LoxP cassette and
formation of the KrasLox-G12D allele
expressing KrasG12D. The anatomy of
the mouse lung is shown (i). Tumour
number and size were estimated at
the endpoint by micro-CT (ii, tumours
in red) or histology (iii) following
40 weeks of induction of mice with
Ad5-mSPC-Cre. The histology image
shows tumours with different
volumes. (B) Comparison of the total
number of tumours detected by micro-
CT and histology in five individual
mice at the endpoint of 40 weeks p.i.
with Ad5-mSPC-Cre. There were
significantly more tumours (P<0.01)
detected by histological analysis
than by micro-CT (mean±s.d.;
**P<0.01, paired Student’s t-test).
(C) Comparison of the total number of
tumours at endpoint (40 weeks p.i.
with Ad5-mSPC-Cre), detected by
micro-CT and histology, grouped
(binned) according to size, in five
individual animals (mean±s.d.;
*P<0.05, paired Student’s t-test).
(D) Size distribution of tumours
detected by micro-CT (top row) or
histology (bottom row) in five
individual mice at endpoint (40 weeks
p.i. with Ad5-mSPC-Cre). The total
number of tumours identified by the
two methods in each animal (n) is
indicated. (E) Comparison of tumour
volumes as determined by micro-CT
and serial sectioning of the entire
tumour, H&E staining and tumour
area quantitation. The two methods
showed a linear correlation.
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that observedwhenmicro-CTwas used (Fig. 1B).A further analysis, in
which tumours were grouped according to volume using data binning,
revealed that the sensitivity of micro-CT for tumour detection was lost
when tumour volume fell below 0.5 mm3, with micro-CT showing a
significantly smaller (P<0.05) tumour number (Fig. 1C,D).
To ensure that micro-CT provides an accurate indication of
individual tumour volume for tumours with volumes above
0.5 mm3, we compared results from micro-CT with those from
tumour area quantitation determined by serial sectioning followed
by Haematoxylin and Eosin (H&E) staining. The two methods
showed a linear correlation (Fig. 1E), indicating that both methods
were concordant for tumour detection above a 0.5-mm3 threshold.
Overall, our data show that micro-CT provides an accurate value for
tumour volumes above a lower limit of 0.5 mm3, consistent with
data from Kirsch and colleagues (Kirsch et al., 2010).
Analysis of tumour histology types
To gain an assessment of the spectrum of lung tumour histology
types, we undertook histopathological evaluation of H&E-stained
lung sections from Kras+/LSL-G12D mice at 20 weeks p.i. with Ad5-
CMV-Cre, and at 40 weeks p.i. induction with Ad5-mSPC-Cre,
using the recommended criteria of mouse lung tumour classification
(Nikitin et al., 2004). Fig. 2A provides representative images of
H&E-stained sections of AAH, adenoma and bronchial lesions in
Ad5-CMV-Cre-infected mice. As previously reported (Jackson et al.,
2001; Sutherland et al., 2014), our analysis showed the presence of
AAH and adenomas in both sets of mice. Adenomas were mostly of
simple papillary pattern but rare small foci of solid growth were
identified. Bronchial lesions were evident in Ad5-CMV-Cre-infected
mice, as expected, but were largely absent from Ad5-mSPC-Cre-
infected mice (Fig. 2B). Lesions of each histological type were
counted (Fig. 2B), and this showed more AAHs/adenomas in the
Ad5-CMV-Cre-infected mice compared with Ad5-mSPC-Cre-
infected mice. However, there was a high degree of inter-mouse
variability, regardless of the type of virus used, for reasons that are
likely related to some variability in the amount of virus inhaled by
individual mice. Interestingly, no overt adenocarcinomas were
observed in either the Ad5-CMV-Cre- or Ad5-mSPC-Cre-infected
Kras+/LSL-G12D mice at the time points analysed.
In vivomonitoring of tumour burden by measuring levels
of total cfDNA
We next assessed whether non-invasive monitoring of lung tumour
development could be achieved by profiling levels of total cfDNA.
Fig. 2. Histological assessment of pathological
alterations in mice expressing the KrasLox-G12D
allele. (A) Representative H&E-stained lung
sections of Kras+/LSL-G12D mice infected with Ad5-
CMV-Cre expression and analysed 20 weeks p.i.
The different pathologies detected in the far left
image are magnified in images i-iii, showing
representative examples of alveolar hyperplasia (i),
papillary adenoma (ii) and papillary endobronchial
lesions (iii). (B) Quantitative assessment of each
pathology detected in H&E-stained sections of lung
tissue collected from Kras+/LSL-G12D mice infected
with either Ad5-CMV-Cre (n 4) or Ad5-mSPC-Cre
(n=3) at endpoint (20 and 40 weeks, respectively).
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We infected Kras+/LSL-G12D mice with viruses carrying either Ad5-
CMV-Cre or Ad5-CMV-βgal (control) for up to 20 weeks
(Fig. 3A), or with Ad5-mSPC-Cre for up to 40 weeks (Fig. 3B),
by intranasal delivery, and monitored tumour development every
2 weeks in the case of Ad5-CMV-Cre/Ad5-CMV-βgal, and every 5-
10 weeks in the case of Ad5-mSPC-Cre, by micro-CT scanning
(Fig. 3A,B, right panels). We collected blood samples for cfDNA
analysis, in parallel with the micro-CT imaging.
We observed a more rapid increase in tumour volume with Ad5-
CMV-Cre infection (Fig. 3A) than with Ad5-mSPC-Cre (Fig. 3B)
infection, whichwas consistent with previously reported data (Jackson
et al., 2001; Sutherland et al., 2014) and the data shown in Fig. 2B. In
Ad5-CMV-Cre-infected mice, tumours larger than 0.5 mm3 were first
detectable by micro-CT at ∼9 weeks p.i. (Fig. 3A), whereas in Ad5-
mSPC-Cre-infected mice, tumours above this threshold were
detectable beginning at 35 weeks p.i. (Fig. 3B).
To assess total cfDNA levels in blood, a quantitative real-time
PCR (qPCR) assay targeting a 113-bp single-copy locus within the
Gapdh genomic region was used. This assay has a dynamic range of
at least 500-fold and can detect the equivalent of one copy (3.3 pg;
one haploid genome equivalent) of Gapdh (R. M. Trigg, Molecular
analysis of circulating cell-free DNA in lung cancer, PhD thesis,
University of Leicester, 2017). As expected, given the lower tumour
burden of the Ad5-mSPC-Cre mice, the cfDNA levels induced by
Ad5-mSPC-Cre were lower than those induced by Ad5-CMV-Cre
(Fig. 3A,B, left panels). However, for tumours of equivalent
volumes, cfDNA levels in Ad5-CMV-Cre- and Ad5-mSPC-Cre-
infected mice were broadly similar, suggesting that KrasG12D
expression in lung resident myeloid cells or BH induced by Ad5-
CMV-Cre had little effect on overall cfDNA release.
A significant increase in cfDNA levels was first detected at
12 weeks p.i. in the case of Ad5-CMV-Cre (Fig. 3A) in comparison
to samples at baseline. However, in the case of Ad5-mSPC-Cre, a
significant increase in cfDNA levels was first detectable at 20 weeks
p.i. (Fig. 3B), but this was not maintained until after 35 weeks p.i.
For Ad5-CMV-βgal, cfDNA levels remained consistently low
throughout the time course (Fig. 3A). These data show that overall
cfDNA levels were increased in mice bearing lesions that were
representative of early pre-malignant lung lesions, without
transition to adenocarcinoma, compared with healthy controls.
For both adenoviral systems, cfDNA levels, as measured by qPCR
analysis, did not reproducibly improve the threshold for tumour
burden compared with micro-CT scanning, although the data for the
20-week time point in Ad5-mSPC-Cre mice potentially suggests
that a more sensitive cfDNA assay method could facilitate this.
Development of a PCR assay to monitor ctDNA through
KrasLox-G12D
Although cfDNA levels can give an indication of tumour burden,
their assessment is not able to distinguish tumour-derived ctDNA
Fig. 3. Monitoring of cfDNA levels usingGapdh analysis
by qPCR. (A) Gapdh levels as measured by qPCR in
cfDNA in comparison to tumour burden in Kras+/LSL-G12D
mice over a time course following infection with Ad5-CMV-
Cre (red) or Ad5-CMV-βgal (blue). Total tumour burden was
quantitated from micro-CT imaging. Gapdh levels were
measured by qPCR of circulating DNA derived from the
plasma of mice at each time point. Mean values are
indicated by diamonds/lines; values for individual mice are
indicated by circles (n=3-12 at each time point). *P<0.05 for
two-tailed unpaired Student’s t-test comparisons between
mean values at a given time point and values at time=0. The
correlation coefficients between Gapdh levels and tumour
burden are indicated (linear regression analysis; P-value,
goodness of fit). (B)Gapdh levels in cfDNA as measured by
qPCR in comparison to tumour burden in Kras+/LSL-G12D
mice over a time course following infection with Ad5-mSPC-
Cre. Mean values are indicated by diamonds/lines; values
for individual mice are indicated by circles (n=4-9 at each
time point). *P<0.05 for two-tailed unpaired Student’s t-test
comparisons between mean values at a given time point
and values at time=0. The correlation coefficients between
Gapdh levels and tumour burden are indicated (linear
regression analysis; P-value, goodness of fit).
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from that derived from apoptosis of other healthy cells. Therefore,
we developed an assay for measuring ctDNA through the detection
of the tumour-derived KrasLox-G12D allele in blood (see Methods in
the supplementary material). Initial studies using endpoint PCR
approaches detected the presence of this allele in the cfDNA of Ad5-
CMV-Cre-infected Kras+/LSL-G12D mice at 12 weeks p.i.
(R. M. Trigg, Molecular analysis of circulating cell-free DNA in
lung cancer, PhD thesis, University of Leicester, 2017),
encouraging the development of a qPCR assay.
An assay that specifically detects the KrasLox-G12D allele was
required, but this proved challenging due to similarities with the
KrasLSL-G12D andKrasWT alleles. A unique 34-bp region that contains
the singleLoxP sequence andhas 13-bppalindromicmotifs flankinga
central 8-bp spacer sequencewas identified (Fig. S1A). This sequence
was determined to have a propensity to form a stem-loop structure
(Fig. S1B) that occludes access to primers and DNA polymerase
(Huang et al., 2007). Moreover, this LoxP sequence is flanked by
palindromic Sal1 restriction sites, which contribute a further 6 bp to
the stem-loop structure; this 19-bp structure (Fig. S1C) has a predicted
melting temperature (Tm) of 65.5°C by in silico prediction using
mFold (Zuker, 2003). To overcome the inhibitory effect of this stem-
loop on PCR amplification, several strategies were attempted.
The first PCR strategy involved targeting the stem-loop with dual-
labelled TaqMan probes incorporating a 3′ minor groove binder
moiety (Fig. S2,MGB-1,MGB-2 orMGB-3). However, this failed to
permit PCR amplification, even when destabilising agents such as
betaine, urea and dimethyl sulfoxide were included (data not shown).
A second strategy was taken in which a hydrolysis probe was
designed to include ‘locked nucleic acid’ (LNA) bases, a chemical
modification that increases both the Tm and binding specificity of the
probe while also providing strand-invasion properties. This LNA
probe, LNA-1 (Fig. S2), permitted qPCR amplification of the
KrasLox-G12D allele, but the efficiency was poor (∼85%; Fig. S3A,B).
To attempt to improve the amplification efficiency, we next adapted
the LNA-1 probe to a droplet digital PCR (ddPCR) assay. Although
this approach provided some discrimination between positive and
negative droplets, therewas an additional clustering of droplets above
the main negative cluster, above 5000 fluorescence units (Fig. S4),
indicating the presence of artefacts caused by autofluorescence.
A second LNA probe, LNA-2 (Fig. S2), was next designed to
destabilise both stem-loops simultaneously, using a ‘double
destabilisation’ strategy (Esposito et al., 2003). The combination
of probe LNA-2 with the 133-bp amplicon primers provided
good discrimination between positive and negative droplets with
Kras+/Lox-G12D genomic DNA as a template (Fig. 4A-D). To determine
the sensitivity of the LNA-2 assay, Kras+/Lox-G12D genomic DNAwas
spiked into a background ofKras+/LSL-G12D genomicDNA and serially
diluted twofold over 11 points (Table S1). To ensure that the
concentration of KrasLSL-G12D in each dilution was constant, the
LNA-2 assay was duplexed with the Gapdh assay, and the copy
number of KrasLox-G12D was calculated by halving that of Gapdh. A
good correlation between the actual and theoretical copy number was
observed down to the tenth dilution, which corresponded to a copy
number of 0.75 and allele frequency of 0.1% (Fig. 4E; Table S1). The
dropout at the 11th dilutionwas consistent with only a 38% chance of a
positive droplet being present, thus confirming the suitability of the
LNA-2 assay for the sensitive detection of KrasLox-G12D in plasma.
Cre-mediated recombination introduces mutations
in the KrasLox-G12D allele
Cre recombinase is known to have DNA-damaging activity
(Loonstra et al., 2001), but its potential for introducing mutations
at target recombination sites, within the KrasLSL-G12D allele, has not
been investigated previously. To investigate whether possible
sequence variation as a result of Cre expression may impact PCR
sensitivity, DNA was extracted from a formalin-fixed paraffin-
embedded section of Kras+/Lox-G12D mouse lung tissue containing
multiple adenomas as determined by histological analysis (Fig.
S5A). A 180-bp region surrounding the recombined LoxP sequence
was PCR amplified and cloned, and 40 individual clones were
sequenced. Sequence alignment revealed point mutations within 12
of the 40 clones, clustered within and around the Sal1 restriction
sites (Fig. S5B,C). To confirm that these mutations were not
induced by errors from the DNA polymerase during PCR
amplification, a 140-bp wild-type (WT) region of the KrasWT
allele co-amplified by PCR in the same reaction was also cloned and
sequenced, but no mutations were identified (data not shown). Thus,
Cre recombination of LoxP sequences introduces point mutations
within target sequences that may have an impact on the efficiency of
PCR amplification.
Monitoring ctDNAbymeasuringKrasLox-G12D levels in plasma
We next applied the ddPCR assay developed above to monitor
levels of the KrasLox-G12D allele in the plasma ctDNA fraction of
Kras+/LSL-G12D mice infected with Ad5-mSPC-Cre over a time
course of 0 to 40 weeks. We chose to perform the analysis in
Ad5-mSPC-Cre-induced mice only, because Ad5-CMV-Cre is
known to induce recombination of the KrasLSL-G12D allele in
non-tumour cells (Kamata et al., 2017). We observed a significant
increase in the number of copies of the KrasLox-G12D allele at
40 weeks p.i compared with samples at baseline, whereas an
increase in tumour volume was evident from 35 weeks onwards
using micro-CT (Fig. 5). There was some variability amongst
different mice, with two of eight animals showing no detectable
KrasLox-G12D allele in blood at 40 weeks p.i. These same two mice
were found to show low tumour volumes, as determined by
micro-CT. Thus, although these data demonstrate that ctDNA can be
detected in the circulation of Kras+/Lox-G12D mice at extended time
points, changes in tumour volume are not reliably detected earlier
by ctDNA than by micro-CT.
DISCUSSION
The overall survival of cancer patients is greatly improved if the
disease is diagnosed at an earlier stage, such as with CT screening in
lung cancer (National Lung Screening Trial Research et al., 2013).
However, the implementation of widespread CT screening in
healthcare pathways is costly and impractical in many cases.
Therefore, cheaper and more tractable alternatives are needed.
With regard to non-small cell lung cancer (NSCLC), extensive
phylogenetic genomic sequencing in the TRACERx trial has
identified evolutionary drivers of the disease (Jamal-Hanjani et al.,
2017). Postoperative serial ctDNA profiling was shown to predict
metastatic relapse in patients with NSCLC, and tumour volume,
measured by CT volumetric analysis, correlated with the mean
clonal plasma ctDNA variant allele frequency, becoming optimally
detectable at volumes greater than 10 cm3 (Abbosh et al., 2017).
The application of ctDNA monitoring to the earlier detection of
lung cancer has been more difficult due to the challenges associated
with the identification of patients with pre-malignant lesions. For
this reason, we modelled this in a well-characterised genetic mouse
model of lung adenocarcinoma development driven by oncogenic
KRAS (Jackson et al., 2001; Sutherland et al., 2014). One of the
major strengths of the autochthonous KrasLSL-G12D mouse model is
the ability to control tumour initiation by exposure to adenoviruses
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expressing Cre recombinase, coupled with the ability to follow
subsequent tumour progression (Shaw et al., 2005). Mice develop
numerous pulmonary lesions, which are predominantly of the
papillary subtype, and these lesions include AAH, resembling
putative precursors of human lung adenocarcinoma (Nikitin et al.,
2004). These progress to small adenomas that enlarge over time,
with some developing into overt adenocarcinomas over prolonged
periods (Jackson et al., 2001). By monitoring the time from Cre
induction, this model enables the investigation of micewith defined,
early-stage lung lesions. We show, for the first time, that cfDNA/
ctDNA is released into the blood in this model and that the cfDNA/
ctDNA level correlates with tumour volume as determined by
micro-CT. Furthermore, rising cfDNA levels and ctDNAwere both
detected without evidence of progression to overtly invasive
adenocarcinomas, suggesting that pre-malignant lung lesions are
able to release fragments of DNA into the circulation.
Using micro-CT, we were able to serially track tumour growth,
and we show that this approach provides an accurate volumetric
measurement of lesions larger than 0.5 mm3 by comparison to
histological quantitation of tumour volumes (Fig. 1E). Contrast
Fig. 4. Validation of ddPCR assay for detection of KrasLox-G12D allele using LNA-2 primers. (A-C) One-dimensional droplet plot of LNA-2 assay (comprising
probe LNA-2 and primers flanking the recombined LoxP sequence in KrasLox-G12D) with Kras+/Lox-G12DMEF genomic DNA (A), Kras+/LSL-G12DMEF genomic DNA
(B) and Kras+/+ MEF genomic DNA (C). Primers were annealed at 62°C, following a gradient PCR experiment to determine the optimum annealing temperature
(Ta, not shown). A manual threshold of 1000 fluorescence units was selected. (D) Kras+/Lox-G12D MEF genomic DNA was serially diluted into a background of
Kras+/LSL-G12D MEF genomic DNA. A one-dimensional droplet plot for the 133-bp LNA-2 assay at each serial dilution is shown. A manual threshold of 1100
fluorescence units was selected. (E) Actual versus theoretical copy number of KrasLox-G12D at each serial dilution.
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agents have been used previously in the Kras+/LSL-G12D mouse
model to better differentiate tumours from the surrounding
vasculature (Lalwani et al., 2013), and detection of smaller
tumours has been enhanced using bioluminescence and
fluorescence biomarkers (Rodriguez et al., 2014). The use of
these additional approaches and/or the implementation of more
advanced, high-resolution techniques – such as positron-emission
tomography or magnetic resonance imaging – would potentially
facilitate the detection of individual tumours with volumes below
0.5 mm3 in the mouse.
Detection of theKrasLox-G12D allele in total cfDNA by PCR proved
extremely challenging due to the palindromic nature of the LoxP
sequence and sequence homology between the KrasWT and KrasLox-
G12D alleles. In addition, data from Fig. S5 show that Cre-mediated
recombination introduces mutations at the recombination site, which
potentially affect the performance of the assay. After multiple
attempts, using several different approaches, a specific ddPCR assay
was developed that was applied to plasma cfDNA samples. To our
knowledge, this represents the first report of assays for detection of
the Cre-recombined KrasLox-G12D allele in KrasLSL-G12D mice.
The comparison between mice infected with Ad5-CMV-Cre and
those infected with Ad5-mSPC-Cre shows that, at similar tumour
burden, there are comparable total cfDNA levels in mice regardless of
the adenovirus used (Fig. 3). This observation suggests that the
infection of lung residentmyeloid lineage cells and/or the development
of bronchial lesions by Ad5-CMV-Cre does not significantly affect the
release of cfDNA, but this requires further exploration.
Total levels of circulating cfDNA are known to increase in
patients with advanced disease (Leon et al., 1977; Madhavan et al.,
2014; Newman et al., 2014). Consistently, we observed an increase
in the total cfDNA concentration in mice with progressive disease
(Fig. 3). However, the relationship between tumour size and cfDNA
concentration in mice was driven primarily by mice with
significantly larger-than-average tumour burden. Notably,
elevated cfDNA/ctDNA was detected in mice with at least 14
tumours larger than 0.5 mm3, combining to a total volume above
7 mm3. For a single mass, this is equivalent to a tumour with
diameter ∼2.5 mm. Although, in humans, CT is able to detect lung
nodules as small as 1 mm in diameter, the malignant potential of
such lesions is unknown and follow-up scans are recommended to
monitor progression of suspicious lesions (Rubin, 2015).
Potentially, cfDNA/ctDNA profiling could be implemented at this
stage to monitor the emergence of larger pre-malignant or, indeed,
malignant lesions and thus avoid multiple CT scanning. However, it
should be borne in mind that the volumes of mouse plasma analysed
in the present study (∼50 µl) relative to total mouse blood volume
(2 ml) are not achievable in humans (typically 2 ml from a total
blood volume of 5 l) and therefore would require the development
of more sensitive assays to profile the appropriate variant alleles.
In summary, we demonstrate the ability to detect the release of
total cfDNA and tumour-derived ctDNA from mice bearing pre-
malignant lung lesions with a total tumour volume in excess of
7.0 mm3. This discovery is potentially encouraging for the use of
cfDNA/ctDNA profiling in the detection of pre-malignant lesions of
the lung adenocarcinoma pathway in humans.
MATERIALS AND METHODS
Animal husbandry
Animal experiments were performed under the UK Home Office (HO)
licence authority. Infected mice (C57BL6/J), both males and females,
randomly selected for treatment, were analysed at experimental endpoints.
Experimental animals underwent regulated procedures with a maximum
severity classification of ‘moderate’ according to the HO guidelines. Kras+/
LSL-G12D mice were genotyped according to the Jacks laboratory-
recommended protocol (https://jacks-lab.mit.edu/protocols/genotyping/
kras_cond). Intranasal inhalation of adenoviral vectors was performed
using Ad5-CMV-Cre, Ad5-mSPC-Cre or Ad5-CMV-βgal in mice with an
age range between 8 and 20 weeks. Mice were anaesthetised with 3%
vapourised isofluorane in oxygen, in an induction chamber. The viral
supernatant (50 µl) was loaded into the nasal aperture of each individual
animal. Viral concentrations were 5×107 plaque-forming units for Ad5-
CMV-Cre and Ad5-CMV-βgal, and 1×108 for Ad5-mSPC-Cre viruses. All
packaged adenoviruses were purchased from the Viral Vector Core Facility
(University of Iowa, Iowa City, IA, USA).
Blood collection and plasma isolation
For longitudinal time points, blood was withdrawn from saphenous veins,
whereas cardiac blood samples were taken at the endpoint. For mouse
saphenous blood sampling, 40 μl was pipetted into 200 μl EDTA (4.5 mM,
pH 8.0) in phosphate-buffered saline (PBS). For cardiac blood sampling,
blood (typically, 200 µl) was collected from terminally anaesthetised mice
into K3-EDTA vacutainers (BD Biosciences). Blood was centrifuged at
1000 g for 10 min, and the plasma supernatant was centrifuged at 1000 g for
a further 10 min. Blood samples were processed promptly to reduce
haemolysis; samples with evidence of haemolysis by visual inspection were
excluded from further analysis. Plasma volumes were adjusted to 200 µl
with PBS before extraction of cfDNA.
Extraction of cfDNA
cfDNA was extracted from 200 µl plasma sample using a QIAamp DNA
Blood Mini kit (Qiagen) and eluted in 50 µl TE buffer (10.0 mM Tris-HCl,
0.5 mM EDTA, pH 8.0). Purified DNA was stored at −20°C prior to use.
Once extracted, the cfDNA concentration was measured using a Qubit 2.0
fluorometer with Qubit dsDNA HS Assay reagents (Thermo Fisher
Scientific), with a detection range of ≥10 pg/µl.
Fig. 5. Detection of the KrasLox-G12D allele in plasma using
ddPCR. Analysis of KrasLox-G12D levels in cfDNA by ddPCR
and the total tumour burden in Kras+/LSL-G12D mice over a
time course following infection with Ad5-mSPC-Cre. Mean
values are indicated by diamonds/lines; values for individual
mice are indicated by circles (n=8-9 at each time point).
*P<0.05 for two-tailed unpaired Student’s t-test comparisons
between mean values at a given time point and values at
time=0. The correlation coefficients between KrasLox-G12D
levels and tumour burden are indicated (linear regression
analysis; P-value, goodness of fit). Datasets for total tumour
volume are also used in Fig. 3.
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Micro-CT imaging
Lung and tumour volumes were quantified using a Quantum FX micro-CT
Imaging System (PerkinElmer). Animals were anaesthetised using a
continuous flow of vapourised isofluorane. Animals were imaged for 34 s
using a field of view of 40 mm with respiratory gating. Each of these scans
subjected the animal to∼20 mGy radiation, a relatively low dosewell within
the range recommended to avoid irradiation artefacts over the course of the
study. To determine volumes for identified tumours and whole lung
volumes, Caliper micro-CT analysis software was used.
Histological analysis of tumours
Lungs were resected and fixed in 4% paraformaldehyde for 24 h at room
temperature. Tissue was then transferred to 70% ethanol and stored at 4°C.
Tissue was embedded in paraffin, and 5 µm sections were cut using a
microtome. For serial sectioning, sections at 100 µm intervals throughout
the entire block were obtained. After sectioning, slides were stained with
H&E as previously reported (Kamata et al., 2015). Stained slides were
photographed using a Leica DM500 microscope and an ICC50 Camera
(Leica), and overlapping images were merged using Adobe Photoshop
(version 13.0.1.1). Slides were also scanned on a NanoZoomer-XR Digital
slide scanner C12000 (Hamamatsu Photonics) and analysed using
NDP.view2 software (Hamamatsu Photonics) to calculate tumour volumes.
Cell culture
Mouse embryonic fibroblasts (MEFs) derived from Kras+/LSL-G12D mouse
embryos were cultured and authenticated by PCR genotyping as previously
described (Andreadi et al., 2012). MEFswere infected with Ad5-CMV-Cre at
a multiplicity of infection of 500, and Kras+/Lox-G12D cells were grown by
continuous culture. Genomic DNA from MEFs was extracted as previously
described (Andreadi et al., 2012).
PCR analysis
Primers used for qPCR analysis of Gapdh in cfDNA were as follows:
forward 5′-CCTCACAATCTGTCTCACCTTATT-3′ and reverse 5′-
GACCTCTGTAAGTCCGCTTTG-3′; a TaqMan probe with the
sequence FAM-AGCCTTATTGTCCTCGGGCAT-BH1 was also used.
For the KrasLox-G12D assay, the following primers were used: forward
5′-CCAGTCAACAAAGAATACCGCAAGG-3′ and reverse 5′-
TCTGCATAGTACGCTATACCCTGTG-3′; a TaqMan probe with the
sequence HEX-TCGACATAACTTCGTATA-BH1 was also used.
Underlined nucleotides represent LNA bases.
qPCR
qPCR was performed as previously described (Rakhit et al., 2017) on the
StepOnePlus Real-Time PCR System (Thermo Fisher Scientific) using
TaqMan Fast Universal PCR Master Mix (Thermo Fisher Scientific).
Thermal cycling conditions were as follows: 95°C for 10 min, followed by
40 cycles of 95°C for 15 s and 60°C (for the Gapdh assay) or 63°C (for the
KrasLox-G12D assay) for 20 s. Reactions were conducted in triplicate,
including a no-template control and a positive control. Gapdh levels were
adjusted for the plasma volume used for each cfDNA extraction.
ddPCR
All reactions for ddPCR analysis were formulated as described previously
(Rakhit et al., 2017). A QX200 Droplet Digital PCR System (Bio-Rad) was
used, using the manufacturer’s protocol and reagents. Thermal cycling
conditions were as follows: 95°C for 10 min; 40 cycles of 95°C for 30 s and
63°C for 30 s; and 98°C for 10 min. The KrasLox-G12D copies were adjusted
for the plasma volume used for each cfDNA extraction. A no-template
control and a positive control were included in every assay. Analysis was
performed according to the manufacturer’s instructions on QuantaSoft
software (Bio-Rad).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6 (www.graphpad.
com). The data are presented as themean value, and the error bars indicate ±s.d.
or ±s.e.m. (as indicated). ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.
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